Capstone Investment Advisors
ALNY icon

Capstone Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capstone Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,300
Closed -$2.11M – 1568
2025
Q4 		$2.11M Buy
+5,300
New +$2.35M ﹤0.01% 606

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capstone Investment Advisors's ALNY Position: Q2 2026 in Review

Capstone Investment Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 152% in Q2 2026, buying an estimated $346K and bringing the position to 1,899 shares worth $572K. The position accounts for ﹤0.01% of the portfolio, ranked #1175.

Capstone Investment Advisors first reported a position in ALNY in Q1 2016 and has held it in 7 quarters since. The position peaked at $3.55M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Capstone Investment Advisors held 1,899 shares of Alnylam Pharmaceuticals worth $572K as of Q2 2026.
  • Capstone Investment Advisors bought 1,146 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $346K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1175 holding.
  • Capstone Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 7 quarters since.
  • Capstone Investment Advisors's Alnylam Pharmaceuticals position peaked at $3.55M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.